Brokers Offer Predictions for CANF FY2026 Earnings

Can-Fite BioPharma Ltd. (NYSE:CANF) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Can-Fite BioPharma in a research report issued to clients and investors on Tuesday, May 12th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($1.04) per share for the year. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Can-Fite BioPharma’s FY2027 earnings at ($0.26) EPS.

Separately, D. Boral Capital upgraded Can-Fite BioPharma from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Wednesday. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Can-Fite BioPharma Trading Up 7.4%

Can-Fite BioPharma stock opened at $3.64 on Thursday. The firm has a market capitalization of $2.38 million, a P/E ratio of -2.03 and a beta of 1.09. Can-Fite BioPharma has a twelve month low of $2.83 and a twelve month high of $23.40. The stock’s fifty day simple moving average is $3.39 and its 200-day simple moving average is $4.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sabby Management LLC raised its holdings in shares of Can-Fite BioPharma by 80.3% in the 3rd quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock valued at $871,000 after purchasing an additional 626,306 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Can-Fite BioPharma during the fourth quarter worth $41,000. Finally, Rhumbline Advisers increased its holdings in Can-Fite BioPharma by 42.4% in the first quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock valued at $57,000 after buying an additional 11,388 shares during the last quarter. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).